Sarcoma News and Research

RSS

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, announced today that it has reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a global pivotal Phase 3 trial with aldoxorubicin as a treatment for patients with soft tissue sarcomas who have relapsed or were refractory following prior treatment with chemotherapy.

24 Apr 2013

Microwave ablation therapy reduces pain in patients with painful bone, soft-tissue tumors

First-of-its-kind research presented today showed microwave ablation therapy cut pain in half for patients with painful bone and soft-tissue tumors and took less time to complete than radiofrequency ablation.

15 Apr 2013

New study shows combination therapy is effective in treating sarcoma tumors

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors.

10 Apr 2013

New immunotherapies are seldom developed for childhood cancer

More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.

9 Apr 2013

Polymer scaffolds can advance the development of cancer therapeutics

Porous polymer scaffolds fabricated to support the growth of biological tissue for implantation may hold the potential to greatly accelerate the development of cancer therapeutics.

3 Apr 2013

Advanced gene sequencing test helps clinicians treat cancer

The University of Washington and Seattle Cancer Care Alliance (SCCA) partnered to launch UW-OncoPlex - an advanced gene sequencing test to help clinicians treat cancer. The new diagnostic tool is a significant milestone in the development of precision medicine and empowers doctors to predict which treatment therapies will be most effective for an individual patient's cancer.

14 Mar 2013

Weekend reading: Deciding if it's 'time to let mom die,' a cancer hospital's controversial admission procedures

My father, sister and I sat in the near-empty Chinese restaurant, picking at our plates, unable to avoid the question that we'd gathered to discuss: When was it time to let Mom die? ... My father and sister looked to me for my thoughts. In our family, after all, I'm the go-to guy for all things medical. I've been a health care reporter for 15 years: at the Dallas Morning News, the Los Angeles Times and now ProPublica.

7 Mar 2013

Study identifies two gene mutations that lead to death of nerve cells in ALS

A study led by St. Jude Children's Research Hospital has discovered mutations in two genes that lead to the death of nerve cells in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and related degenerative diseases.

4 Mar 2013

Kaposi’s sarcoma risk factors revealed

Scientists have uncovered an intriguing relationship between the risk for Kaposi’s sarcoma, smoking, and the use of highly active antiretroviral therapy.

25 Feb 2013

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) hide within the worldwide human population. While dormant in the vast majority of those infected, these active herpesviruses can develop into several forms of cancer.

14 Feb 2013

University of Utah geneticists engineer mice that develop clear cell sarcoma

Geneticists led by University of Utah Nobel Prize Laureate Mario R. Capecchi, Ph.D., have engineered mice that develop clear cell sarcoma (CCS), a significant step in better understanding how this rare and deadly soft tissue cancer arises. The mouse model also can potentially speed the development of drugs to target genes that must be activated for the cancer to form.

13 Feb 2013

Burkitt lymphoma risk after transplantation highlighted

Solid organ transplant recipients have a significant risk for developing Burkitt lymphoma (BL), US researchers have found.

12 Feb 2013

ADRB receptors play a direct role in Src activation by PKA-mediated mechanism

Scientists at The University of Texas MD Anderson Cancer Center have discovered the signaling pathway whereby a master regulator of cancer cell proteins - known as Src - leads to ovarian cancer progression when exposed to stress hormones. The researchers report in the current issue of Nature Communications that beta blocker drugs mitigate this effect and reduce cancer deaths by an average of 17 percent.

30 Jan 2013

UCLA, NanoSmart partner to develop novel cancer drug delivery platform

NanoSmart Pharmaceuticals, a private biotechnology company, has entered into a research collaboration agreement with University of California Los Angeles (UCLA) to continue the development of NanoSmart's novel drug delivery platform for the treatment of cancer and other life-threatening diseases.

17 Jan 2013

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Liposarcoma, the most common type of sarcoma, is an often lethal form of cancer that develops in fat cells. It is particularly deadly, in part, because the tumors are not consistently visible with positron emission tomography (PET) scans that use a common probe called FDG and because they frequently do not respond to chemotherapy.

11 Dec 2012

Researchers discover LSD-1 enzyme as important target for treatment of Ewing sarcoma

Discovery of a new drug with high potential to treat Ewing sarcoma, an often deadly cancer of children and young adults, and the previously unknown mechanism behind it, come hand-in-hand in a new study by researchers from Huntsman Cancer Institute (HCI) at the University of Utah. The report appears in today's online issue of the journal Oncogene.

26 Nov 2012

Nonfunctional MED12 gene linked to chemotherapy resistance

Research published in Cell shows that people with tumors that have a nonfunctional version of the mediator 12 gene are resistant to drugs used to treat lung and colon cancer such as gefitinib.

26 Nov 2012

Regorafenib able to control resistant gastrointestinal stromal tumor

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.

21 Nov 2012

IDMC reviews data from Nanobiotix’s NBTXR3 Phase I study on advanced soft tissue sarcoma

Nanobiotix, announced today that the Independent Data Monitoring Committee (IDMC) has reviewed the data of the first 6 patients treated in the phase I Study with the lead product NBTXR3 for the treatment of advanced Soft Tissue Sarcoma of the extremity. Based on the review of the safety data, the IDMC has unanimously recommended continuing the enrollment in the study according to the protocol. This trial is realized in the Institut Gustave Roussy, France.

13 Nov 2012

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, “Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials” to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.

30 Oct 2012